Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer
The purpose of this study is to learn about the effects of two new anticancer drugs, erlotinib (Tarceva) and bexarotene (Targretin), when treating patients with advanced lung cancer. Erlotinib is approved by the Food and Drug Administration (FDA) for the treatment of non-small-cell lung cancer (NSCLC). Bexarotene is approved by the FDA for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.
Checked against the public recordLast updated Jan 8, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Konstantin Dragnev
- Interventions being studied
- Drug: erlotinib and bexarotene
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Advanced NSCLC * Prior chemotherapy or radiotherapy is allowed. Exclusion Criteria: * Hepatic or renal dysfunction
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Norris Cotton Cancer CenterLebanon, New Hampshire
- Mount Sinai School of MedicineNew York, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 8, 2019. Always confirm current availability with the study team.